Close

International Medical Devices and Supplies Fair Opens in Hong Kong

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...
- Advertisement -

The eighth HKTDC Hong Kong International Medical Devices and Supplies Fair opened today at the Hong Kong Convention and Exhibition Centre (HKCEC).

Organised by the Hong Kong Trade Development Council (HKTDC) and co-organised by the Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA), the three-day fair (16-18 May) showcases the latest medical equipment, technology and related services, providing a one-stop business platform for the medical industry.

This year’s Medical Fair welcomes a record 270 exhibitors from 14 countries and regions. The HKTDC has also organised 37 buying missions, bringing more than 1,400 buyers to the fair, including representatives of Ziwell Medical (S) PTE LTD and NTUC Unity Healthcare Co-operative Ltd from Singapore, ServiPlus Medical Equipment Inc from the Philippines, Malaysia’s Felco Medical Supplies Sdn Bhd, and Health-Care Equipment from the United Kingdom.

“The aging population and increasing awareness of healthcare needs have resulted in a flourishing global demand for medical and healthcare products,” said HKTDC Deputy Executive Director Benjamin Chau. “As technological advances are hugely important in the medical devices industry, there is also growing demand for new equipment for the medical industry. In response to the rapid development of the medical devices and healthcare industries, the Medical Fair is launching the new ‘World of Healthcare’ and ‘Startup’ zones. The Medical Fair also features a number of specialised products zones, including the ‘Household Medical Products’ zone and ‘Rehabilitation and Elderly Care’ zone, creating a comprehensive trading platform to help the industry grasp the rapidly growing medical supplies market.”

New pavilions present the latest equipment and technology
This year, the Medical Fair welcomes new group pavilions from the US State of Illinois, as well as from the Czech Republic, India and Poland’s Wielkopolska region. An exhibitor from the United States is showcasing a professional ultrasonic fetal heart monitor and surgical equipment for gynecological cryotherapy. Returning pavilions include those from the Chinese mainland’s Ningbo city, Pakistan and the HKMHDIA, which comprises about 30 companies. Exhibitors from Korea, Singapore and Thailand also made their debut at the fair, further enriching the variety of medical equipment and devices on show.

Debut of “World of Healthcare” and “Startup” zones
Responding to growing awareness of the importance of personal health, the fair introduces the “World of Healthcare” to present healthcare products and services, including fitness products, health food and beverages, and nutritional supplements. The medical industry is also becoming a popular sector for entrepreneurs, with many start-ups developing new medical supplies and technologies in recent years. The “Startup” zone, which is being introduced at the Medical Fair this year, showcases the creativity of Hong Kong start-ups, allowing them to meet with buyers and potential business partners to explore new business opportunities. One of the start-ups offers an automated full bathing system with temperature control, surrounding water jets and warm-air drying, and features that reduce the risk of falls during a shower (Booth no: 3G-D23). Another start-up is showcasing a series of products for treating and relieving back pain (Booth no: 3F-J03).

Special zones for quality medical equipment and technology
Organised into more than 15 specialised product zones for easy sourcing, the Medical Fair gathers a wide spectrum of medical and healthcare equipment and services. According to the United Nations, the total global population is estimated at around 7.5 billion people, with 960 million or 13 per cent of the total population who are aged 60 or above in 2017. To keep pace with rising demand in the “silver market,” the Rehabilitation and Elderly Care zone showcases products and services for general care and rehabilitation after illness or injury among elderly people. Products include an exercise machine equipped with various muscle-training programmes that improve respiratory and cardiovascular system functions among patients with Parkinson’s disease (Booth no: 3F-F15), as well as an innovative tank-top developed by the Hong Kong Polytechnic University, which features a bio-feedback system with multiple sensors used to treat scoliosis (Booth no: 3F-F09). As household medical products and services grow more popular, many companies have launched products specific to the household market. The Household Medical Products zone, another fair highlight, presents various household medical devices, including an electrocardiograph smart-watch band (Booth no: 3F-G03) that can facilitate immediate diagnosis and treatment of heart disease.

With new innovations in medical technology, there is growing demand for diagnostic and surgical equipment. The Hospital Equipment zone showcases specialist equipment and technology, including ultrasound and imaging tools, as well as a range of surgical instruments. The fair’s Physiotherapy zone presents the latest physiotherapy equipment, devices and related services and products, including a therapy mattress, therapy light, physiotherapy plinth and physiotherapy massage equipment.

Seminars to analyse market trends
To help industry professionals monitor the pulse of the market and expand their business networks, a series of seminars are being organised. Today’s (16 May) events include a seminar on “The Hottest Trends Revolutionising the Medical and Healthcare Device Industries”; the Continuing Medical Education workshop on “Disease Prevention: Cervical Cancer and HPV Infection”, co-organised with the Hong Kong Doctors Union; as well as the Continuing Nursing Education workshop, co-organised with the Hong Kong Health Care Federation. The Czech Republic pavilion, participating in the fair for the first time, will invite professionals to present an overview of the Czech medical market and their latest medical equipment and services tomorrow (17 May). Representatives from the Hong Kong Electrical Appliance Industries Association and Hong Kong Medical and Healthcare Device Industries Association will also speak at the seminar “Sparking Innovation: The Game Changers of the Healthcare Sector”. The seminar on “Worldwide Medical Device Regulatory Updates” and the Continuing Medical Education workshop “Coronary Angioplasty: Update for Daily Clinical Practice 2017” will be held on 18 May.

Professor John Leong Chi-yan, Chairman of Hong Kong’s Hospital Authority, was the officiating guest at today’s networking reception (16 May). Offering added synergy with the fair, the Hospital Authority Convention 2017 (16-17 May) is expected to bring in more than 5,000 delegates, making it one of Asia-Pacific’s largest events for medical professionals.

Hong Kong’s total exports of medical and healthcare equipment reached HK$12.8 billion in 2016, an increase of 8.1 per cent over the previous year, with favourable growth in many markets such as the Chinese mainland, the US, ASEAN and the UK.

Hong Kong International Medical Devices and Supplies Fair:www.hktdc.com/hkmedicalfair

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »